The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
EGFR and KRAS mutations during anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer: Clinically relevant?
Lucie Karayan-Tapon
No relevant relationships to disclose
Aurelie Ferru
No relevant relationships to disclose
Ulrich Cortes
No relevant relationships to disclose
Claire Villalva
No relevant relationships to disclose
Jean Marc Tourani
No relevant relationships to disclose
Christine Silvain
No relevant relationships to disclose
Pierre Levillain
No relevant relationships to disclose
David Tougeron
No relevant relationships to disclose